Long-term safety check for NTLA-2002 recipients
Part of Genetic & congenital, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study follows people who previously got the experimental drug NTLA-2002 in an Intellia trial. It checks long-term safety and health effects, even if you already stopped treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received at least one dose of NTLA-2002 in a previous Intellia trial.
- You must agree to join this follow-up study by signing a consent form.
- You must be willing to come to scheduled visits and follow the study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This study checks how people are doing long-term after receiving NTLA-2001 in an Intellia clinical trial. If you previously took part and agree to be followed, this may help the researchers understand lasting safety and effects.
This study is testing a new gene-silencing treatment called NTLA-2001 for people with hereditary ATTR amyloidosis that causes nerve damage. It works by stopping the body from making a faulty protein that builds up and harms nerves.
This study tests a new treatment, NTLA-2001, for people with a type of heart disease called transthyretin amyloidosis with cardiomyopathy. It aims to see if the medicine can help improve heart function and quality of life.
This study follows up with people who previously took part in a clinical trial testing an experimental gene therapy for critical limb ischemia (severe leg pain or sores due to blocked arteries). It aims to see how well the treatment works over time. If you were in that earlier trial and received at least one dose, joining this follow-up could help researchers learn more about the therapy's lasting effects.
This trial is a continuation study for people who are already getting benefit from a Lilly study that has ended. It checks the long-term safety of the study drug.
Hear when a new Hereditary Angioedema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.